The new survey, which was conducted by the Primary Care Collaborative, The Larry A. Green Center, and 3rd Conversation, features information collected from more than 580 primary care clinicians in 47 states, the District of Columbia, and Guam. The survey was conducted from Oct. 16 to Oct. 19.
Pfizer’s vaccine consists of genetic material called mRNA encased in tiny particles that shuttle it into our cells. From there, it stimulates the immune system to make antibodies that protect against the virus. A similar strategy is employed in other leading COVID-19 vaccine candidates. If mRNA vaccines can protect against COVID-19 and, presumably, other infectious diseases, it will be a momentous piece of news.
The health system, which features 23 hospitals and 800 ambulatory sites, treated about 20,000 hospitalized COVID-19 patients during the spring surge, says Mark Jarrett, MD, MBA, senior vice president, chief quality officer, and deputy chief medical officer at Northwell.
The industrial hygiene “hierarchy of controls” is a series of workplace safety and health interventions that begins with elimination of hazards, followed by substitution, then engineering controls, administrative controls (including work practices), and personal protective equipment.
A joint development agreement between BreathTech Corporation, a subsidiary of Austin, Texas-based Astrotech, and Cleveland Clinic focuses on using a non-invasive device that will analyze breath samples to identify COVID-19 strains.
In the authors’ hospital of practice, patients who required isolation at the hospital had to adhere to strict infection control protocols, and some did not have a readily available caregiver who could room with them. While provisions were made for these patients to receive some of their essential belongings from home such as their gadgets, phones, and toys, many were unable to access them owing to caregiver challenges, giving rise to feelings of isolation and displacement.
On episode 14 of PSQH: The Podcast, host Jay Kumar talks to LRC Systems founder and CEO Dr. Shailesh Date about how U.S. hospitals have responded to COVID-19, what to expect as we enter flu season, thoughts about a potential vaccine, and the threat of co-infections. This episode is part of PSQH’s celebration of International Infection Prevention Week and is brought to you by Angelini Pharma and GOJO, the inventors of Purell.
Using electronic medical record data gleaned from Epic Health Research Network, the KFF researchers looked at total hospital admissions and non-COVID-19 admissions by patient sex, age, and region to calculate the actual admissions as a share of total predicted admissions for 2020 based on past trends.
The United States has led the world in reported coronavirus deaths. As of Oct. 15, more than 221,000 Americans had died of COVID-19, according to worldometer. The country with the next highest death count was Brazil at more than 150,000.
The co-authors of the recent research article wrote that the study provides “provisional support” for using ECMO to treat coronavirus patients with acute hypoxemic respiratory failure. “In ECMO-supported patients with COVID-19 and characterized as having ARDS, estimated in-hospital mortality 90 days after ECMO initiation was 38.0%, consistent with previous mortality rates in non-COVID-19 ECMO-supported patients with ARDS and acute respiratory failure.”